#Coronavirus Disease Research #References (by AMEDEO, July 19 '25)

 

Antiviral Res

1. LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
   SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
   Antiviral Res. 2025;241:106235.
   PubMed         Abstract available
   
   

   
   BMJ

2. ARETOULI E, Malik M, Widmann C, Parker AM, et al
   Cognitive and mental health outcomes in long covid.
   BMJ. 2025;390:e081349.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

3. SIZA C, Plucinski M, Lessa FC, Campelo E, et al
   Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
   Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
   PubMed         Abstract available
   
   
4. SHOHAM S, Dioverti MV
   Combination Therapy for Protracted COVID-19: When More is More.
   Clin Infect Dis. 2025 Jul 16:ciaf384. doi: 10.1093.
   PubMed        
   
   
5. LITTLE JS, Edelstein GE, Swank Z, Choudhary MC, et al
   Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
   Clin Infect Dis. 2025 Jul 16:ciaf383. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

6. GURLEY ES, Plowright RK
   A Roadmap of Primary Pandemic Prevention Through Spillover Investigation.
   Emerg Infect Dis. 2025;31.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

7. FORD JS, Wang RC, Stephenson B, Degesys NF, et al
   N95((R)) filtering facepiece respirator contamination with SARS-CoV-2 following reuse and extended use.
   Infect Control Hosp Epidemiol. 2025 Jul 14:1-6. doi: 10.1017/ice.2025.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

8. VAIDIE J, Demiselle J, Gabriel A, Guillon A, et al
   Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study.
   Intensive Care Med. 2025 Jul 16. doi: 10.1007/s00134-025-08024.
   PubMed         Abstract available
   
   

   
   J Infect

9. MOOSA F, Kleynhans J, Makhathini L, du Plessis M, et al
   Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 - 2018: findings from the PHIRST study.
   J Infect. 2025;91:106550.
   PubMed         Abstract available
   
   

   
   J Med Virol

10. HUNG CT, Wang LM, Lee YJ, Suk CW, et al
    Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study.
    J Med Virol. 2025;97:e70494.
    PubMed         Abstract available
    
    
11. KIM DH, Kim KS, Kim JH, Lim KB, et al
    Cross-Species Transmission of SARS-CoV-2 From Dogs to Hamsters and Pathological Changes in the Brain.
    J Med Virol. 2025;97:e70496.
    PubMed         Abstract available
    
    

    
    J Virol

12. CARLOCK MA, Pierce SR, Ross TM
    Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
    J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
    PubMed         Abstract available
    
    

    
    JAMA

13. PRASAD V, Makary MA
    US FDA Safety Labeling Change for mRNA COVID-19 Vaccines.
    JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.12675.
    PubMed        
    
    

    
    Lancet

14. NEPOGODIEV D, Picciochi M, Ademuyiwa A, Adisa A, et al
    Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.
    Lancet. 2025 Jul 14:S0140-6736(25)00985-7. doi: 10.1016/S0140-6736(25)00985.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

15. BROSH-NISSIMOV T
    Refining COVID-19 care for immunocompromised patients.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00316.
    PubMed        
    
    
16. WEINSTEIN E, Paredes R, Gardner A, Almas M, et al
    Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00221.
    PubMed         Abstract available
    
    
17. OGBUAGU O, Goldman JD, Gottlieb RL, Singh U, et al
    Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00238.
    PubMed         Abstract available
    
    
18. FLAMANT A, Demirjian A, Lamagni T, Toubiana J, et al
    Invasive group A streptococcal infections: lessons learned from the 2022-23 upsurge.
    Lancet Infect Dis. 2025 Jul 9:S1473-3099(25)00343.
    PubMed         Abstract available
    
    

    
    Science

19. COHEN J, Kaiser J
    NIH suspends alleged 'gain-of-function' studies.
    Science. 2025;389:223-224.
    PubMed         Abstract available